Explain the recent Updates in Heart failure management According to AHA 2026 guidelines

Reading File

Searching the Web

AHA 2026 heart failure guidelines updates

Reading Web Page

https://newsroom.heart.org/news/global-experts-update-heart-…

Finding Sources

Searching PubMed

"heart failure" AND guidelines

Reading Web Page

https://www.youtube.com/watch?v=ibEQhMPKRjo

Finding Sources

Searching PubMed

"heart failure" AND "SGLT2" AND management

Reading File

Searching the Web

2026 second universal definition heart failure new classification LVEF stages staging treatment

Searching PubMed

"heart failure" AND "universal definition" AND classification

I now have comprehensive data from the latest 2026 AHA/ACC/ESC consensus document and supporting clinical evidence. Let me compile a thorough response.

Recent Updates in Heart Failure Management - AHA/ACC/ESC 2026

The most significant 2026 document is the "Second Universal Definition of Heart Failure" (Walsh MN, Kober L, Sliwa K et al.), published simultaneously on June 29, 2026 in Circulation, JACC, European Heart Journal, and Global Heart - a joint consensus by AHA, ACC, ESC, and World Heart Federation, in collaboration with HFSA, HFA, and the Japanese Heart Failure Society (PMIDs: 42366997, 42370864, 42366993, 42403666).

Important note: This is an expert consensus/definition document, not a full clinical practice guideline. The full AHA/ACC Heart Failure Guideline is expected in late 2027.

1. New Classification of HF by Ejection Fraction

The 2026 document makes a major conceptual shift: moving away from rigid LVEF numerical cutoffs toward clinically actionable groups. The prior framework of HFrEF (≤40%), HFmrEF (41-49%), HFpEF (≥50%) is replaced with three simplified, clinically meaningful categories:

Category	Definition
HF with Reduced EF (HFrEF)	Reduced LVEF (below sex/age/ethnicity-adjusted normal)
HF with Preserved EF (HFpEF)	Normal or near-normal LVEF
HF with Improved EF (HFimpEF)	Previously reduced LVEF that has increased or normalized

Key nuance: The lower limit of normal LVEF is now specified as approximately 53% for women and 52% for men, and is slightly higher among Asian individuals - reflecting sex, age, and ethnic differences that the old fixed thresholds ignored. The mid-range EF category (HFmrEF) has been effectively absorbed into the broader framework rather than existing as a hard-cutoff group.

2. Reaffirmed and Refined Disease Staging (with Stage 0)

The document reaffirms the four-stage Universal Classification from 2021 but adds Stage 0:

Stage	Description
Stage 0	No risk factors (new addition)
Stage A	At risk for HF - risk factors present (hypertension, obesity, T2DM, etc.) but no structural changes, symptoms, or biomarker elevation
Stage B	Pre-HF - structural abnormalities, abnormal cardiac function, OR elevated biomarkers, but no symptoms
Stage C	Symptomatic HF - structural cardiac abnormality + current or prior symptoms
Stage D	Advanced HF - severe symptoms at rest or minimal exertion, recurrent hospitalizations, refractory to guideline-directed medical therapy (GDMT)

The framework now emphasizes that prevention is primary - data show dramatically better outcomes in Stage 0/A patients compared to those with even early symptoms (Stage C1/C2).

3. Universal Classification of HF Causes

For the first time, a standardized etiologic classification is proposed - aimed at standardizing reporting in trials and registries and enabling targeted therapy beyond generic GDMT:

Infective cardiomyopathy: viral myocarditis, Chagas disease, HIV, Lyme disease
Inflammatory cardiomyopathy: autoimmune, sarcoidosis, hypersensitivity, desmoplakin
Ischemic cardiomyopathy: ischemic heart disease, MI, CAD
Infiltrative cardiomyopathies: cardiac amyloidosis (ATTR and AL), Fabry disease
Genetic/inherited: familial dilated cardiomyopathy, hypertrophic cardiomyopathy
Other: toxin-mediated, peripartum, stress-induced (Takotsubo)

4. Therapeutic Shifts: From "Quadruple" to "Heart Function" Paradigm

HFrEF - Quadruple Therapy Becomes Standard

The 2026 framework cements quadruple therapy as the cornerstone for HFrEF, a notable shift in terminology from "guideline-directed medical therapy" to optimizing "heart function":

ACE inhibitor / ARB / ARNI (sacubitril-valsartan preferred over ACE inhibitor)
Beta-blocker (carvedilol, metoprolol succinate, bisoprolol)
MRA (spironolactone or eplerenone - non-steroidal finerenone increasingly favored)
SGLT2 inhibitor (dapagliflozin or empagliflozin)

The acronym "HACK" has emerged in clinical teaching as a mnemonic for the four pillars, emphasizing that all four should be initiated simultaneously and early rather than sequentially.

SGLT2 Inhibitors - Pan-EF Indication

A landmark recognition in 2026: SGLT2 inhibitors are the only drug class with evidence across the entire EF spectrum - HFrEF, HFmrEF, and HFpEF. The benefit appears even in patients hospitalized for HF, as supported by the DAPA ACT HF-TIMI 68 trial and meta-analysis (PMID 40884036, Circulation 2025). SGLT2 inhibitors should be started unless eGFR is <15-20 mL/min/1.73m².

Notably, benefit onset differs: in HFrEF, clinical benefit is seen within ~30 days; in HFpEF, within ~2 weeks - suggesting the mechanism is hemodynamic/neurohormonal rather than structural remodeling.

HFpEF - Triple Drug Evidence-Based Therapy

This is arguably the most dramatic change since 2010:

SGLT2 inhibitors (dapagliflozin, empagliflozin): Class I evidence in HFpEF
Non-steroidal MRA (finerenone): positive outcomes data in HFpEF
GLP-1 receptor agonists (semaglutide, tirzepatide): emerging pivotal trial data showing CV outcomes benefit in HFpEF with obesity/T2DM - a major paradigm shift for the cardiometabolic HFpEF phenotype

HFpEF has moved from "no indicated therapies" in 2010 to triple evidence-based therapy in 2026, with the SGLT2 inhibitor receiving clinical primacy.

HFmrEF - Now Evidence-Supported

The 2026 document acknowledges that HFmrEF, which wasn't even a recognized phenotype in 2010, now has dedicated evidence-based therapy - primarily from SGLT2 inhibitor and non-steroidal MRA data.

5. Geographic Variation in HF

The document formally acknowledges that geographic and ethnic variation in HF risk, causes, and outcomes must be factored into classification and management. This is the first universal definition to address this explicitly - for example, Chagas disease predominating in Latin America, rheumatic heart disease in sub-Saharan Africa, and higher LVEF thresholds in Asian individuals.

6. HF Trajectories: Remission and Recovery

The new framework explicitly recognizes HF as not a static condition. Three trajectories are now formally acknowledged:

Improvement (partial recovery of function)
Remission (symptoms resolved but disease present)
Recovery (near-complete normalization - previously called HFimpEF)

This is clinically meaningful as it guides continuation vs. tapering of GDMT and signals that reverse remodeling is a real therapeutic goal, not just an aspirational concept.

7. Related 2026 Scientific Statements

Alongside the Second Universal Definition, AHA published:

"Strategies for Optimizing Heart Failure Care in the Older Adult" (June 2026) - addressing frailty, polypharmacy, and goals-of-care in elderly HF
"Risk-Based Primary Prevention of Heart Failure" (March 2025) - a framework for identifying and treating Stage A patients before structural disease develops

Summary Table: What Changed in 2026

Domain	Before (2022 Guidelines)	2026 Update
LVEF classification	HFrEF ≤40%, HFmrEF 41-49%, HFpEF ≥50%	Reduced, Preserved, Improved EF - sex/age/ethnicity adjusted
Staging	Stage A-D	Stage 0 added; refined descriptions
HFrEF treatment	Quadruple therapy recommended	Quadruple therapy standard; simultaneous initiation emphasized
HFpEF treatment	Diuretics only (symptomatic)	SGLT2i + non-steroidal MRA + GLP-1 agonists
Etiology classification	Not standardized	Universal etiologic taxonomy proposed
Geographic variation	Not addressed	Formally incorporated
Disease trajectory	Static framing	Remission / Recovery / Improvement recognized

Bottom line: The 2026 AHA/ACC/ESC consensus redefines heart failure in a more biologically nuanced and clinically actionable way - departing from rigid LVEF cutoffs, formalizing etiology-based classification, and recognizing that HFpEF and HFmrEF now have real pharmacological targets. The full AHA/ACC clinical practice guideline is expected in late 2027 and will operationalize these updates into formal recommendations with evidence grading.

Search for clinical images and ECG patterns of HFpEF vs HFrEF

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Finding Sources

Searching the Web

HFpEF vs HFrEF ECG patterns clinical imaging echocardiogram comparison 2024 2025

Loading Image

Searching the Web

HFrEF ECG left bundle branch block LVH dilated cardiomyopathy ECG findings site:litfl.com OR site:ecgwaves.com

Loading Image

Searching the Web

HFpEF echocardiogram concentric hypertrophy diastolic dysfunction Doppler E/e ratio image

Loading Image

I now have excellent clinical images and ECG patterns. Let me compile the comprehensive response.

Clinical Images & ECG Patterns: HFpEF vs HFrEF

Overview: Key Distinguishing Features

Feature	HFrEF	HFpEF
LVEF	≤40%	≥50% (2026: sex/age adjusted)
LV size	Dilated (eccentric hypertrophy)	Normal/small (concentric hypertrophy)
LV wall	Thin or normal	Thickened
Primary dysfunction	Systolic (pump failure)	Diastolic (relaxation/filling failure)
ECG hallmark	LBBB, LVH with strain, pseudoinfarction Q waves	LVH strain pattern, AF, low QRS voltage (amyloid)
Typical patient	Male, post-MI, younger	Female, elderly, hypertensive, obese

ECG Patterns

HFrEF (Dilated Cardiomyopathy) ECG

The following is an ECG from a patient with ischaemic dilated cardiomyopathy (HFrEF), sourced from LITFL ECG Library:

Ischaemic dilated cardiomyopathy ECG showing LVH, lateral ST changes, and pseudoinfarction Q waves

Key ECG findings in HFrEF / Dilated Cardiomyopathy:

Left Bundle Branch Block (LBBB) - broad, notched R waves in I, aVL, V5-V6; deep S in V1 - present in ~25-30% of HFrEF patients
Pseudoinfarction Q waves - abnormal Q waves in V1-V4 mimicking anterior MI (no culprit artery)
Left atrial enlargement - deep, wide terminal portion of P wave in V1; leftward P-axis deviation
Biventricular hypertrophy - high QRS voltages in precordial leads (V4-V6) with relatively low limb lead voltages
Lateral ST-T changes - downsloping ST depression and T-wave inversion in I, aVL, V5-V6 due to strain

The following shows biventricular hypertrophy in another HFrEF patient:

ECG of dilated cardiomyopathy with biventricular hypertrophy - tall R waves and deep S waves across precordium

Clinical note: No ECG pattern is specific to DCM/HFrEF. However, a completely normal ECG has a very high negative predictive value for significant LV systolic dysfunction (NPV ~98%).

HFpEF ECG Patterns

HFpEF does not have a single "signature" ECG pattern, but common findings reflect its underlying causes:

1. Left Ventricular Hypertrophy (LVH) with Strain - most common HFpEF ECG pattern

Sokolow-Lyon criteria positive: S(V1) + R(V5/V6) > 35 mm
Cornell criteria: R(aVL) + S(V3) > 28 mm (men), >20 mm (women)
LVH strain pattern: downsloping ST depression + T-wave inversion in lateral leads (I, aVL, V5, V6) - reflects concentric LV hypertrophy from long-standing hypertension

2. Atrial Fibrillation - seen in 30-40% of HFpEF patients (dilated LA from elevated filling pressures)

3. Low QRS Voltage in Limb Leads - important "red flag" for cardiac amyloidosis (a major HFpEF cause in elderly patients). The combination of increased LV wall thickness on echo + low voltage on ECG is classic for amyloid.

4. Left Atrial Enlargement - bifid P waves (P mitrale) in II, biphasic in V1

Echocardiographic Findings (the diagnostic cornerstone)

HFpEF Echocardiography - Doppler Parameters

The image below shows the four key echocardiographic measurements used in HFpEF diagnosis (HFA-PEFF scoring algorithm):

HFpEF echocardiographic Doppler parameters: (A) mitral valve E-wave/A-wave ratio, (B) TDI e' velocity, (C) tricuspid valve velocity (TR Vmax for PASP), (D) enlarged LA volume - all used in HFA-PEFF scoring

Doppler parameters explained:

(A) MV E/A ratio - In HFpEF with impaired relaxation (Grade I): E/A < 1 (A-wave dominant). In severe diastolic dysfunction (Grade III): E/A > 2 (restrictive filling - very elevated filling pressures)
(B) TDI e' (tissue Doppler e' velocity) - Reduced e' (septal <7 cm/s, lateral <10 cm/s) reflects impaired myocardial relaxation. E/e' ratio >14 indicates elevated LV filling pressures
(C) TR Vmax - Elevated tricuspid regurgitation velocity (>2.8 m/s) indicates pulmonary hypertension from elevated LA pressure
(D) LA volume index - Enlarged LA (>34 mL/m²) reflects chronically elevated LV filling pressures

Grades of Diastolic Dysfunction (HFpEF Spectrum)

Grade	E/A	e'	E/e'	LVEDP
Grade I (impaired relaxation)	<1.0	Low	≤14	Normal
Grade II (pseudonormal)	1.0-2.0	Low	>14	Elevated
Grade III (restrictive)	>2.0	Low	>14	Severely elevated

HFrEF vs HFpEF Echo: Structural Comparison

Echo Parameter	HFrEF	HFpEF
LVEF	≤40%	≥50%
LV cavity	Dilated (LVEDV increased)	Normal/small
LV geometry	Eccentric hypertrophy (↑LV mass, normal RWT)	Concentric hypertrophy (↑LV mass, ↑RWT)
Wall thickness	Normal/thin	Increased (>12 mm)
Systolic function (GLS)	Severely reduced global longitudinal strain	Mildly reduced GLS (subclinical)
Mitral annular excursion (MAPSE)	Very reduced	Mildly reduced or normal
Diastolic function	Restrictive pattern common (Grade III)	Impaired relaxation (Grade I-II)
LA size	Dilated	Dilated (secondary to elevated filling pressures)
RV	Often dilated (volume overload)	May be dilated (atrial secondary TR in HFpEF)

HFrEF Treatment Algorithm (from Goldman-Cecil Medicine)

The image below shows the complete GDMT treatment pathway for HFrEF (Stage C):

HFrEF treatment flowchart: Step 1 initiate ARNI/ACEi/ARB + beta-blocker + MRA + SGLT2i, Step 2 titrate to target dose, Step 3 patient scenarios (LBBB → CRT-D, LVEF≤35% → ICD, Black patients NYHA III-IV → hydralazine+nitrates), Step 4 device therapy, Step 5 reassess LVEF, Step 6 referral for cardiac transplant/LVAD/palliative care

Goldman-Cecil Medicine, p. 479

Device therapy note from ECG context:

CRT-D is indicated for HFrEF with LVEF ≤35% + LBBB on ECG (QRS ≥150 ms) + NSR + NYHA Class II-III (ambulatory IV)
ICD is indicated for LVEF ≤35% + NYHA Class I-III with >1 year expected survival
LBBB on ECG in a patient with HFrEF is therefore not just a diagnostic finding - it directly triggers a device therapy decision

HFpEF Diagnostic Algorithm (HFA-PEFF)

From the ESC/HFA consensus, diagnosis of HFpEF follows a stepwise scoring:

Step 1 - Pretest (P): Clinical evaluation, ECG, labs, chest X-ray

ECG: LVH criteria, AF, low voltage
Labs: BNP ≥35 pg/mL or NT-proBNP ≥125 pg/mL (in sinus rhythm)

Step 2 - Echo + BNP score (E):

Major criteria (2 points each):

Septal e' <7 cm/s OR lateral e' <10 cm/s
E/e' ratio >15
LA volume index >34 mL/m²
LV mass index >149 g/m² (men) or >122 g/m² (women)
TR velocity >2.8 m/s (PASP >35 mmHg)
NT-proBNP >220 pg/mL (sinus) or >660 pg/mL (AF)

Score ≥5 = HFpEF confirmed. Score ≤1 = HFpEF excluded. Score 2-4 = proceed to Step 3.

Step 3 - Functional testing (F): Exercise stress echo or invasive hemodynamics (LVEDP >16 mmHg or PCWP >25 mmHg with exercise)

Step 4 - Etiology workup (F): Cardiac MRI, genetic testing, nuclear imaging for amyloid (pyrophosphate scan), endomyocardial biopsy

Clinical Summary: Pattern Recognition

Clinical Clue	Think HFrEF	Think HFpEF
Age/Sex	Younger males	Older females
History	Post-MI, DCM, chemotherapy	Hypertension, obesity, DM, AF
ECG	LBBB, pseudoinfarction Q waves	LVH strain, AF, low voltage
Echo	Dilated LV, EF <40%, eccentric hypertrophy	Normal EF, thick walls, diastolic dysfunction
BNP	Very high (proportional to degree of dysfunction)	Elevated but lower (may be "diluted" in obese)
Response to diuretics	Dramatic symptomatic improvement	Narrow therapeutic window - easily overdiuresed
Chest X-ray	Cardiomegaly + pulmonary vascular congestion	Variable - may show minimal cardiomegaly

Sources: Goldman-Cecil Medicine p. 2296-2303; Braunwald's Heart Disease p. 1035; Textbook of Clinical Echocardiography Table 75; LITFL ECG Library - Dilated Cardiomyopathy; ACC HFpEF 2025 Review

This is a shared conversation. Sign in to Orris to start your own chat.